



## Pharvaris to Present Deucricitbant Clinical Data at Upcoming Congresses

March 6, 2024

ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- [Pharvaris](#) (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the [3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema \(ITACA\)](#), to be held from March 14-16, 2024, in Milan, Italy, and the [2024 HAE International \(HAEi\) Regional Conference Americas](#), to be held from March 15-17, 2024, in Panama City, Panama. Details of the presentations are as follows:

### 3rd ITACA National Congress, Milan, Italy, March 14-16, 2024.

- **Title:** Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucricitbant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks  
**Presenter:** Mauro Cancian, M.D., Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
- **Title:** Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucricitbant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial  
**Presenter:** Giuseppe Spadaro, M.D., Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
- **Title:** Prophylactic Treatment with Oral Deucricitbant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema  
**Presenter:** Andrea Zanichelli, M.D., Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
- **Title:** Need for Caregiver Support for People Living With Hereditary Angioedema in European Countries  
**Presenter:** Andrea Zanichelli, M.D., Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, March 15, 4:30 p.m. CET (11:30 a.m. EDT)
- **Title:** Efficacy and Safety of Oral Deucricitbant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial  
**Presenter:** Mauro Cancian, M.D., Ph.D.  
**Format:** Selected Oral and Poster Presentation  
**Date, time:** Saturday, March 16, 10:00 a.m. CET (5:00 a.m. EDT)

### 2024 HAEi Regional Conference Americas, Panama City, Panama, March 15-17, 2024.

- **Title:** Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucricitbant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design  
**Presenter:** Anete Grumach, M.D., Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, March 15, 8:20 p.m. EDT
- **Title:** Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucricitbant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial  
**Presenter:** Markus Magerl, M.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, March 15, 8:20 p.m. EDT
- **Title:** Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucricitbant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks  
**Presenter:** Marcus Maurer, M.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, March 15, 8:20 p.m. EDT
- **Title:** Efficacy and Safety of Oral Deucricitbant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial  
**Presenter:** Marc A. Riedl, M.D., M.S.  
**Format:** Oral Presentation  
**Date, time:** Saturday, March 16, 10:30 a.m. EDT
- **Title:** Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of

Untreated HAE Attacks: Results from a Real World Survey

**Presenter:** William Lumry, M.D.

**Format:** Oral Presentation

**Date, time:** Saturday, March 16, 12:15 p.m. EDT

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: <https://ir.pharvaris.com/news-events/events-presentations>.

**About Pharvaris**

Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit <https://pharvaris.com/>.

**Contact**

Maggie Beller

Executive Director, Head of External and Internal Communications

[maggie.beller@pharvaris.com](mailto:maggie.beller@pharvaris.com)